SELECT: semaglutide reduced cardiovascular events in people without diabetes

17,604 participants with prior cardiovascular disease and overweight or obesity, followed for almost 40 months.

SELECT enrolled 17,604 people aged 45 or older with established cardiovascular disease, a body-mass index of 27 or more and no diabetes. They were randomly assigned to weekly semaglutide or placebo.

After a mean follow-up of 39.8 months, semaglutide was superior to placebo in reducing the composite of cardiovascular death, non-fatal heart attack or non-fatal stroke. It is one of the largest trials ever run with a peptide of this family.

In three points

Human trial with 17,604 participants
Fewer major cardiovascular events than placebo
Benefit seen in people without diabetes

Compounds mentioned

Semaglutide

Original source: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
PubMed · New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.